2B78:F:F-iShares Healthcare Innovation UCITS ETF USD (Acc) (EUR)

ETF | Others |

Last Closing

USD 7.152

Change

+0.07 (+0.93)%

Market Cap

N/A

Volume

3.59K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-28 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

+0.29 (+1.13%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.70 (+1.41%)

USD 115.04B
FRCJ:F UBS MSCI Japan Socially Respon..

+0.15 (+0.69%)

USD 83.57B
SXR8:F iShares Core S&P 500 UCITS ETF..

+7.24 (+1.46%)

USD 80.45B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+0.58 (+1.10%)

USD 76.57B
EUNL:F iShares Core MSCI World UCITS ..

+1.07 (+1.20%)

USD 72.04B
SXRZ:F iShares VII PLC - iShares Nikk..

+2.55 (+1.14%)

USD 58.19B
XDNY:F Xtrackers MSCI Japan ESG Scree..

+0.17 (+1.17%)

USD 56.18B
VUSA:F Vanguard Funds Public Limited ..

+1.71 (+1.93%)

USD 51.63B
VUAA:F Vanguard S&P 500 UCITS Acc

+1.68 (+1.90%)

USD 49.95B

ETFs Containing 2B78:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.33% 56% F 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.33% 55% F 56% F
Trailing 12 Months  
Capital Gain -19.22% 13% F 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.22% 12% F 29% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -4.53% 16% F 30% F
Dividend Return -4.53% 16% F 28% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.11% 57% F 77% C+
Risk Adjusted Return -44.87% 16% F 9% A-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.